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OBJECTIVES This study was designed to evaluate the ability of microvolt-level T-wave alternans (MTWA)
to identify prospectively patients with idiopathic dilated cardiomyopathy (DCM) at risk of
ventricular tachyarrhythmic events and to compare its predictive accuracy with that of
conventional risk stratifiers.
BACKGROUND Patients with DCM are at increased risk of sudden death from ventricular tachyarrhythmias.
At present, there are no established methods of assessing this risk.
METHODS A total of 137 patients with DCM underwent risk stratification through assessment of
MTWA, left ventricular ejection fraction, baroreflex sensitivity (BRS), heart rate variability,
presence of nonsustained ventricular tachycardia (VT), signal-averaged electrocardiogram,
and presence of intraventricular conduction defect. The study end point was either sudden
death, resuscitated ventricular fibrillation, or documented hemodynamically unstable VT.
RESULTS During an average follow-up of 14 6 months, MTWA and BRS were significant univariate
predictors of ventricular tachyarrhythmic events (p  0.035 and p  0.015, respectively).
Multivariate Cox regression analysis revealed that only MTWA was a significant predictor.
CONCLUSIONS Microvolt-level T-wave alternans is a powerful independent predictor of ventricular tachya-
rrhythmic events in patients with DCM. (J Am Coll Cardiol 2003;41:2220–4) © 2003 by
the American College of Cardiology Foundation
Idiopathic dilated cardiomyopathy (DCM) represents the
substrate for approximately 10% of sudden cardiac deaths
(SCDs) in the adult population (1). Mortality in patients
with DCM ranges between 10% and 50% annually, mainly
determined by the severity of the disease (2).
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Recently, it has been demonstrated that in patients with
a history of sustained ventricular tachycardia (VT) or
aborted SCD, the implantable defibrillator (ICD) is supe-
rior to antiarrhythmic pharmacotherapy in prolonging life
(3–5). In these studies, a significant proportion of enrolled
patients suffered from DCM. Even in DCM patients
without aborted SCD but with syncope as the initial
presentation, in whom no arrhythmias could be provoked at
electrophysiologic (EP) testing, there was a high incidence
of appropriate device therapy (6). However, a recently
published study in 104 patients with DCM and a left
ventricular ejection fraction (LVEF) 0.30 who randomly
either did or did not receive the device failed to show benefit
from prophylactic ICD therapy (7). This emphasizes the
need of better identification of DCM patients at high risk of
arrhythmogenic death. Moreover, widespread application of
such a risk stratification approach requires noninvasive,
inexpensive, and easy-to-perform risk stratification methods.
Analysis of microvolt-level T-wave alternans (MTWA)
from the surface electrocardiogram (ECG) has been intro-
duced as a new approach for evaluating arrhythmogenic risk
(8–11). Microvolt-level T-wave alternans analysis involves
the detection of alterations in T-wave morphology that
occur on an every-other-beat basis. Microvolt-level T-wave
alternans is thought to reflect the occurrence of localized
action potential alternans, which creates dispersion of re-
covery, which in turn promotes the development of reen-
trant arrhythmias. In a recent study in patients with heart
failure, MTWA was shown to predict the occurrence of
arrhythmias (12). However, in that study the majority of
patients suffered from coronary artery disease as the under-
lying structural heart disease. Other investigators have
studied the association between MTWA and presence of
Holter-documented VT in DCM patients (13), retrospec-
tively analyzed the relationship between MTWA and prior
ventricular tachyarrhythmic events in DCM patients (14),
and evaluated MTWA as a predictor of ventricular tachy-
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arrhythmic events in mixed populations of patients with
ischemic and non-ischemic cardiomyopathy (15). Only one
other study has evaluated the prognostic value of MTWA in
DCM patients (16). Accordingly, this study reports on
noninvasive risk stratification in a consecutive series of
patients with proven DCM, with particular emphasis on the
potential role of MTWA determination.
METHODS
Patient population. Consecutive patients referred to the
heart failure clinic of the J. W. Goethe University for
diagnosis or for management of heart failure, or to the EP
laboratory of the same institution for evaluation of symp-
tomatic arrhythmias, were considered for entry in the
present study. Patients were eligible for participation if the
following inclusion criteria were met: 1) a confirmed diag-
nosis of DCM according to accepted criteria (17) (including
selective coronary and left ventricular angiography in all
patients); 2) no intercurrent illnesses limiting life expect-
ancy; and 3) presence of sinus rhythm at initial presentation.
Risk stratification was performed at the first clinical visit/
hospitalization when patients were in stable clinical condi-
tion. All patients gave informed consent before entering the
study.
Follow-up. After discharge, patients were seen in the
arrhythmia outpatient clinic at four, eight, and 12 months
and at six-month intervals thereafter. Antiarrhythmic med-
ications remained unchanged during follow-up. Informa-
tion about deceased patients was obtained from family
members, their general practitioners, and the hospitals to
which they had been admitted. Particular attention was
given to the circumstances of each death.
Measurement of MTWA. Microvolt-level T-wave alter-
nans was measured during bicycle exercise, as previously
described (10–12). Microvolt-level T-wave alternans was
prospectively defined (18) to be positive when sustained
alternans were present at the resting heart rate (HR) or had
an onset HR 110 beats/min. Microvolt-level T-wave
alternans was prospectively defined to be negative if the
criteria for positivity were not met and at least 1 min of
artifact-free data without significant alternans was identified
while the HR was maintained at either a level 105
beats/min or within 5 beats/min of the maximum HR (as
long as the maximum HR was at least 80 beats/min and the
patient exercised to maximal effort limited by fatigue or
cardiorespiratory symptoms). Microvolt-level T-wave alter-
nans was classified as indeterminate otherwise. Interpreta-
tion of MTWA tests was carried out prospectively by a
reader (D.M.B.) blinded to clinical data.
Conventional risk stratifiers. Risk assessment included
determination of LVEF, HR variability, mean 24-h RR
interval, presence of nonsustained VT, baroreflex sensitivity
(BRS), and analysis of signal-averaged ECG as previously
reported (12). For the tests with continuous variable results,
the following cutpoints were prospectively used to define
high-risk groups: LVEF 35%; mean RR 700 ms; for
HR variability; standard deviation of normal-to-normal
intervals 70 ms; and BRS 3.0 ms/mm Hg. Intraventric-
ular conduction defect (IVCD) was defined as a QRS
duration of 120 ms.
Definition of end points. With respect to risk stratifica-
tion, the following events were prospectively defined as end
points of the study: sudden death (19) as death occurring
instantaneously within 60 min of a change in symptoms or
unexpectedly during sleep; cardiac arrest due to ventricular
fibrillation (VF) documented by the emergency service; or
hemodynamically unstable VT or VF documented by elec-
trogram storage of an ICD. Heart transplantation was not
considered as an end point, but follow-up of patients was
censored at the time of this procedure.
Statistics. Kaplan-Meier analysis was used to perform the
univariate analyses of the cumulative probability of events in
conjunction with the log-rank test. Cox regression analysis
was used for the multivariate analysis test using the SAS
software package (SAS Institute Inc., Cary, North Caroli-
na). The survival curves in each case were computed starting
at the date of risk stratification. Statistical measures of
sensitivity, specificity, positive and negative predictive accu-
racy, relative risk, and their standard deviations were com-
puted from the values and standard errors of survival at the
18-month time point. Data are given as mean  SD. The
hypotheses being tested were single-sided (patients with a
positive clinical test result have a higher future event rate
than patients with a negative clinical test result), and thus p
values reflect single-sided statistical tests. A statistical sig-
nificance level of p  0.05 was used. Patients with indeter-
minate results were not included in the statistical analyses.
RESULTS
Study population and events during follow-up. A total of
137 patients with nonischemic DCM, 31 women and 106
men with a mean age of 55  11 years, were enrolled in the
study (Table 1). At study entry, 37 patients (27%) had been
fitted with an ICD because of a prior history of cardiac
arrest (n  15), documented sustained VT (n  12),
Abbreviations and Acronyms
BRS  baroreflex sensitivity
DCM  dilated cardiomyopathy
ECG  electrocardiogram/electrocardiograph/
electrocardiographic
EP  electrophysiological
HR  heart rate
ICD  implantable cardioverter-defibrillator
IVCD  intraventricular conduction defect
LVEF  left ventricular ejection fraction
MTWA  microvolt-level T-wave alternans
NSVT  nonspecific ventricular tachycardia
SCD  sudden cardiac death
VF  ventricular fibrillation
VT  ventricular tachycardia
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syncope (n  6), or for prophylactic reasons (n  4). In the
remaining 100 patients, there was no prior history of
VT/VF or aborted SCD.
In the entire cohort, LVEF averaged 0.29  0.11.
Sixty-four percent of patients were treated with digoxin,
91% with angiotensin-converting enzyme inhibitors, 65%
with beta-blockers, and 81% with diuretics. The only
antiarrhythmic drug used was amiodarone, which was ad-
ministered to 29 patients (21%).
Patients were followed for up to 18 months (mean 14 
6 months). During the follow-up period, one of the pre-
specified study end points was observed in 18 patients. Four
patients died suddenly, 3 suffered from unstable VT, and 11
were successfully resuscitated from VF. In addition, three
patients died from pump failure and two from a noncardiac
cause. Six patients underwent heart transplantation.
T-wave alternans. The MTWA outcome was positive in
66 patients (48%), negative in 34 (25%), and indeterminate
in 37 (27%). Eighteen of the 37 patients with indeterminate
results failed to achieve an HR of 105 beats/min. Of the
event patients, 13 were positive, 2 negative, and 3 indeter-
minate. By Kaplan-Meier analysis, MTWA (p  0.035)
was a statistically significant predictor of events (Fig. 1).
Conventional risk stratifiers. The outcomes of bifurcated
conventional risk stratification were as follows (Table 2):
LVEF was 0.35 in 79%, BRS was 3.0 ms/mm Hg in
49%; mean RR was 700 ms in 34%; nonspecific ventric-
ular tachycardia (NSVT) was present in 36%; signal-
averaged ECG was positive in 24% and indeterminate in
38%; SDNN was 70 ms in 38%; and IVCD was present
in 48 patients (35%).
Only MTWA and BRS were statistically significant
univariate predictors of events in the entire population
(Table 2, Fig. 1).
Multivariate analysis. The outcomes of the various risk
stratification methods were subjected to a Cox regression
analysis with the occurrence of end points as the dependent
variable. The final model of this analysis included MTWA
as the only independent statistical predictor of arrhythmic
events (chi-square value 3.87; p  0.045). We also at-
tempted to adjust for additional covariates of age, gender,
and extent of disease as measured by LVEF, but the sample
size was too small to allow for this adjustment.
Patients with ICDs. The end point event rate (as deter-
mined by Kaplan-Meier analysis) in patients with prior
ICDs was 33% at 18 months of follow-up versus 8% in
patients without ICDs (p 0.001). Eleven end point events
occurred among the patients with ICDs, and seven among
patients without ICDs. In patients with ICDs versus
patients without ICDs, the number of patients with a
positive MTWA test was 23 (62%) versus 43 (43%) (p 
0.04), the number with a negative MTWA result was 5
(14%) versus 29 (29%) (p  0.05), and the number with an
Table 1. Patient Characteristics
Age (yrs) 55  11
Male gender (% patients) 77
Medication (% patients)
Digoxin 64
ACE inhibitors 91
Beta-blocker 65
Diuretics 81
Amiodarone 21
Mean follow-up (months) 14  6
LVEF (%) 29  11
NSVT (% patients) 36
BRS (ms/mm Hg) 4.1  4.4
MTWA (patients/%)
Positive 66 (48%)
Negative 34 (25%)
Indeterminate 37 (27%)
IVCD present (% patients) 35
SDNN (ms) 90  49
SAECG  (%) 24
ACE  angiotensin-converting enzyme; BRS  baroreflex sensitivity; IVCD 
intraventricular conduction disturbance; LVEF  left ventricular ejection fraction;
MTWA  microvolt-level T-wave alternans; NSVT  nonsustained ventricular
tachycardia; SAECG  signal-averaged electrocardiogram; SDNN  standard
deviation of NN intervals.
Figure 1. Kaplan-Meier event-free survival curves for microvolt-level
T-wave alternans (TWA) and baroreflex sensitivity (BRS). p values relate
to log-rank test.
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indeterminate test result was 9 (24%) versus 28 (28%) (p 
NS). The ICD and non-ICD patient subgroups were too
small for MTWA to achieve statistical significance within
each subgroup. However, the relative risk for MTWA
predicting end point events among ICD patients was 2.4 
2.2, and for non–ICD patients 1.93  2.2.
DISCUSSION
This prospective study is the first to compare the prognostic
value of noninvasive assessment of MTWA to a variety of
other currently used risk stratification methods in patients
with DCM. The results show that determination of
MTWA and BRS are useful in predicting risk for future
tachyarrhythmic events in this patient population.
Risk stratification for arrhythmogenic death in DCM.
The prognosis of patients with DCM has been reported to
be poor, with mortality rates up to 50% over a two-year
follow-up period (2,20). Recent therapeutic advances have
improved survival of DCM patients significantly, as indi-
cated by recently published prospective studies (7,21). Nev-
ertheless, sudden arrhythmogenic death is continuing to be
one of the leading causes of death in DCM (1).
Depressed left ventricular function appears to be the most
powerful risk predictor, but in general it is a better predictor
of overall than of arrhythmogenic mortality. At present,
there are no reliable strategies to identify DCM patients
specifically at high risk for sudden death. For instance, EP
testing in DCM has been shown to be of limited value
(22,23). Likewise, the presence of NSVT has been evaluated
as a marker of arrhythmogenic risk, although the data are
mixed (21,24). In a recent prospective study, however,
NSVT did not identify DCM patients who would benefit
from ICD (21). Few studies have aimed to identify DCM
patients at risk for arrhythmogenic death by evaluating
autonomic tone (25,26). For example, Yi and colleagues
recently showed that reduced HRV is a marker of progres-
sive heart failure (25). However, the prognostic power of
autonomic markers for prediction of arrhythmogenic death
in DCM remains to be demonstrated. Thus, despite the
availability of a very effective therapeutic modality to prevent
sudden death—the ICD (3–5)—at present no reliable risk
stratification method exists to identify specifically those
DCM patients who would benefit from prophylactic device
therapy (7).
Repolarization abnormalities to identify DCM patients
at risk for tachyarrhythmic events. At a cellular level,
myocardium isolated from failing animal and human hearts
reveals significant EP abnormalities, including repolariza-
tion (27). There is experimental evidence that alteration of
repolarizing K channel expression in failing myocardium
predisposes to those repolarization abnormalities that may
give rise to malignant reentry arrhythmias (27). Accord-
ingly, it has been proposed to evaluate the prognostic yield
of new ECG measures of repolarization, such as QT
interval dispersion (27) or MTWA (10–12,16). Concerning
the first method, some investigators found prognostic in-
formation of prolonged QT dispersion in CHF (27), others
did not (28).
Microvolt-level T-wave alternans is a new promising
noninvasive method of evaluating repolarization abnormal-
ities. Experimental and clinical observations indicate that
MTWA can be associated with an increased propensity for
serious ventricular arrhythmias. The precise EP basis for
MTWA remains to be elucidated; at present, the most likely
hypothesis is that alterations in action potential duration
occurring discordantly in the myocardium cause dispersion
of recovery, which leads to wavefront fractionation and
reentry. Evidence for this mechanism as the major predictor
for MTWA has recently been provided by experiments
applying the technique of high-density optical mapping
with voltage-sensitive dyes to a guinea pig Langendorff
preparation (29). Repolarization phases of the action poten-
tials exhibited significant alternans-type beat-to-beat oscil-
lations corresponding to ECG-observed MTWA. As to the
ionic mechanisms underlying MTWA, it has been recently
shown that beat-to-beat changes in intracellular Ca2
modulate the repolarizing currents in the heart, thus con-
tributing to MTWA (30).
The results of the present study demonstrate that
MTWA-positive patients are at particularly high risk for
tachyarrhythmic events. Perhaps equally important is the
finding that only occasional patients with a negative
MTWA test suffered from a sustained VT or sudden death.
Before the present study, only one smaller series has recently
been published that examined the prognostic value of
Table 2. Statistical Measures of Performance of Different Risk Stratifiers
Test N Sensitivity Specificity PPV NPV RR p Value
MTWA 137 0.87  0.08 0.38  0.02 0.22  0.05 0.94  0.04 3.44  2.51 0.035
BRS  3.0 ms/mm Hg 122 0.74  0.10 0.55  0.02 0.22  0.06 0.93  0.04 3.00  1.64 0.015
NSVT 118 0.47  0.13 0.66  0.02 0.17  0.06 0.90  0.04 1.61  0.84 0.185
SAECG 128 0.47  0.15 0.63  0.02 0.17  0.07 0.88  0.05 1.43  0.84 0.280
IVCD 137 0.40  0.11 0.66  0.02 0.17  0.06 0.86  0.04 1.22  0.55 0.326
Mean RR  700 ms 118 0.37  0.12 0.67  0.02 0.14  0.06 0.88  0.04 1.16  0.62 0.258
LVEF  35% 137 0.80  0.08 0.21  0.01 0.15  0.04 0.86  0.07 1.07  0.56 0.472
SDNN  70 ms 117 0.30  0.12 0.61  0.02 0.10  0.05 0.86  0.04 0.71  0.40 0.364
N  number of patients for whom test data are available; NPV  negative predictive value; p value  p value of log-rank test from Kaplan-Meier analysis; PPV  positive
predictive value; RR  relative risk. Other abbreviations as in Table 1.
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MTWA in DCM. Kitamura et al. followed these patients
over a mean of 21 months, during which 12 arrhythmic
events occurred (16). Similar to our study, these authors
found that MTWA was a powerful risk stratifier in this
patient population. Clearly, these findings as well as ours
need to be confirmed in future interventional trials evaluat-
ing the benefit of prophylactic ICD implantation.
Study limitations. In the present study, 27% of patients
were enrolled after having received an ICD. These patients
had themselves already declared as being at high risk.
However, we decided to include them in our study to enrich
the number of predefined study end points in order to
facilitate evaluation of MTWA as a new risk stratification
method. Moreover, only hemodynamically unstable ventric-
ular tachyarrhythmic events were counted as end points in
these ICD recipients. In this study, 27% of patients had an
indeterminate MTWA result, 49% of whom failed to
achieve an HR of 105 beats/min during exercise. Improve-
ments in the exercise protocol and in MTWA analysis
technology are expected to reduce this rate in the future.
Conclusions. The findings of this prospective study indi-
cate that noninvasive determination of MTWA, particularly
when assessed together with autonomic markers such as
BRS, holds promise in identifying DCM patients at high
risk of future ventricular tachyarrhythmic events.
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